(MMPs) are thought to be intimately involved. 14 There is no proven medical therapy for AAA, with management of patients relying on routine monitoring of AAA size by ultrasound until surgical repair is implemented when the growth rate exceeds 10 mm/y or the diameter exceeds 55 mm.
Although the physiological function(s) of SAA have not been clearly established, several studies link SAA with inflammatory processes implicated in AAA formation and progression, such as leukocyte chemotaxis, 15 induction of inflammatory cytokines, [16] [17] [18] and upregulation of genes involved in extracellular matrix remodeling, including transforming growth factor-β (TGF-β) 19 and MMP expression. [20] [21] [22] [23] To investigate the possibility that SAA plays a role in the initiation or progression of AAA, mice lacking both acute-phase SAA isoforms 24 were bred into a C57BL/6 background and then crossed with apoE −/− mice, which allowed us to take advantage of the widely used AAA model that involves infusing angiotensin II (Ang II) into hypercholesterolemic mice. Ang II-induced AAAs exhibit many features of human AAA, including medial degeneration, inflammation, thrombus formation, and rupture of the abdominal aorta. 25 Our results demonstrate that SAA augments MMP activity in the abdominal aorta and enhances AAA expansion in Ang II-infused apoE −/− mice.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

SAA Induces Genes Implicated in AAA
SAA has been reported to elicit proinflammatory effects, such as macrophage chemotaxis, inflammatory cytokine and MMP induction in multiple cell types in vitro. 15, 17, 20, 23, 26, 27 However, conclusions made in many of the published studies have recently come under question because of the recognition that the commercially available hybrid SAA molecule used in these studies may exert activities not shared by naturally expressed SAA isoforms. 28, 29 In this study, we provide novel data that SAA1.1/SAA2.1 isolated from acute-phase mouse plasma stimulates primary mouse aortic smooth muscle cells (SMCs; Figure 1A ) and J774 macrophage-like cells ( Figure 1B) to express MMPs and inflammatory cytokines. This result demonstrates that SAA may exert direct effects on vascular cells that affect vessel wall integrity.
SAA Expression Is Induced in Ang II-Treated apoE −/− Mice
In addition to being a potent vasoactive peptide, Ang II is known to elicit proinflammatory effects through activation of NF-κB. 30 Thus, it was of interest to determine whether Ang II administration induces expression of acute-phase SAA. Compared with saline-injected apoE −/− mice, hepatic SAA mRNA ( Figure 2A ) was increased ≈26-fold (P<0.001) and plasma SAA concentrations ( Figure 2B) (P<0.062) 17-fold increase in hepatic SAA mRNA abundance ( Figure 2C ) and a significant 15-fold increase in plasma SAA concentration ( Figure 2D ). SAA mRNA expression was also significantly upregulated in abdominal aortas of SAAWT mice after 10 days of Ang II infusion ( Figure 2E ), but not in the thoracic aorta of Ang II-infused SAAWT mice (P=0.083; Figure 2F ). Taken together, our data indicate that systemic and vascular expression of acute-phase SAA is elevated in Ang II-administered apoE −/− mice.
SAA Is Present in Ang II-Induced AAA and Colocalized With Macrophages, Elastin Breaks, and MMP Activity
An early response to chronic Ang II infusion in hypercholesterolemic mice is macrophage infiltration into the media of the abdominal aorta, particularly in regions of elastin degradation. 31 To investigate the possibility that SAA may be involved in these events, we performed immunohistochemical analyses throughout the entire length of AAA in apoE −/− mice (SAAWT) infused with Ang II for 10 days. This time interval was chosen based on previous studies demonstrating the significant tissue remodeling and inflammation after 10-day Ang II infusion. 31, 32 As expected, aneurysmal tissue exhibited considerable heterogeneity along the length of the aorta ( Figure 3A) , with transmural breaks of elastin fibers evident in some ( Figure 3D , asterisk) but not all ( Figure 3C ) sections. Regions containing elastin breaks were distinguished by intense MMP activity (green fluorescent staining by in situ zymography) and prominent macrophage and SAA immunoreactivity (red staining). In contrast, in regions with intact elastin lamina, MMP activity was primarily localized to acellular regions (ie, thrombus), and macrophage and SAA immunostaining were relatively less pronounced. The specificity of SAA and macrophage immunoreactivity was confirmed by staining sections in the absence of primary antibodies ( Figure I in the online-only Data Supplement); the specificity of our in situ zymography experiments was confirmed by performing the staining procedure in the presence of an MMP inhibitor ( Figure I in the online-only Data Supplement). In our experience, ≈30% of mice do not develop AAA during Ang II infusion, consistent with published studies in male apoE −/− mice. 33 Analysis of the aorta from a nonresponsive mouse ( Figure 3B ) demonstrated the presence of an intact elastin lamina throughout the length of the abdominal aorta, with minimal MMP activity, macrophage infiltration, or SAA immunostaining ( Figure 3E ). Importantly, SAA can also be detected by immunohistochemistry in human 
SAA Deficiency Protects Mice From Ang II-Induced AAA
To investigate the role of SAA in the pathogenesis of Ang IIinduced AAA, apoE −/− mice were bred with mice lacking both acute-phase SAA isoforms, SAA1.1 and SAA2.1. 24, 34 Both apoE −/− and apoE −/− mice lacking SAA (designated SAAWT and SAAKO, respectively) were on the C57BL/6 background, bred normally, and appeared to be in good physical health before the study. Some mice died during the course of Ang II infusion because of aortic rupture, consistent with previous reports. 31, 32 Although the incidence of rupture for mice infused with Ang II for 28 days was similar for SAAWT (4 of 20 mice; 20%) and SAAKO (3 of 20 mice; 15%), all of the ruptures in SAAKO mice occurred in the thoracic region, whereas 3 of 4 ruptures were localized to the abdominal region of SAAWT mice ( Figure III in the online-only Data Supplement). In subsequent studies, whereby mice were infused with Ang II for 10 days, we noted a trend for regional differences in aortic rupture in the 2 strains (see below). AAA progression was assessed in surviving mice by in vivo ultrasound and computer-assisted morphometric analyses ex vivo to determine the maximal luminal and external diameters of the abdominal aorta, respectively. Before Ang II infusion, luminal diameters were not significantly different in SAAWT mice (1.30±0.01 mm; n=25) compared with SAAKO mice (1.29±0.02 mm; n=25). As expected, 28-day saline infusion did not significantly alter aortic luminal diameters in either strain (data not shown). Relative to baseline measures, Ang II infusion produced a significantly greater increase in maximal diameters of abdominal aorta lumens of SAAWT mice (99.5±12.4% increase) compared with SAAKO mice (44.5±8.5% increase; P<0.001; Figure 4A ; representative ultrasound images shown below). Consistently, the maximal external diameter of the abdominal aorta increased significantly with Ang II infusion in both genotypes but was significantly greater for SAAWT mice (2.90±0.30 mm) compared with SAAKO mice (1.53±0.14 mm; P<0.001) after Ang II infusion ( Figure 4B ; representative ex vivo images shown below). The overall incidence, calculated as the percent of total mice that died from aortic rupture plus the percent of total mice that developed AAA (defined in surviving mice as ≥50% dilation of abdominal aorta lumen), was significantly increased in Ang II-infused SAAWT mice (80%) compared with SAAKO mice (40%; P<0.05; Figure III in the onlineonly Data Supplement). Thus, both incidence and severity of Ang II-induced AAAs were reduced in SAAKO compared to SAAWT mice. 
SAA Deficiency Does Not Result in a Generally Suppressed Response to Ang II Infusion
SAA Deficiency Does Not Alter Ang II-Induced Aneurysm Formation or Atherosclerotic Lipid Deposition in the Aortic Arch Region of apoE −/− Mice
In addition to promoting AAA, subcutaneous infusion of Ang II into hypercholesterolemic mice also leads to a significant dilation of the ascending aorta and augments atherosclerotic lipid accumulation. [36] [37] [38] To investigate whether SAA contributes to these Ang II-induced vascular pathologies, we quantified the intimal surface area of the aortic arch region as an index of ascending AA 36, 39 
Ang II-Induced MMP-2 Expression and Activity Are Blunted in Abdominal Aortas of SAAKO Mice
In a previous study, we reported that 10-day Ang II infusion results in significantly increased MMP-2, MMP-13, and MMP-14 mRNA abundance and enhanced MMP-2 activity, in abdominal aortas of apoE −/− mice. 32 To investigate whether SAA mediates increased MMP expression in Ang II-infused mice, aortas were collected from SAAWT and SAAKO mice after 10-day saline or Ang II infusion for quantitative reverse transcription polymerase chain reaction and gel zymography. During the short-term Ang II infusion, 5 SAAWT mice (≈21%) died from aortic rupture (3 abdominal and 2 thoracic) and 5 SAAKO mice (≈21%) died (2 abdominal and 3 thoracic ruptures). A subset of surviving mice was imaged by ultrasound 9 days after pump implantation to assess AAAs. Consistent with 28-day infusion studies described above, there were no significant differences in baseline measures of luminal diameters between SAAWT and SAAKO mice, and saline infusion did not cause significant luminal expansion in either strain. Relative to baseline values, maximal luminal diameters were increased to a greater extent in SAAWT (54.7±14.4%; n=12) compared with SAAKO (28.6±5.1%; n=8) mice, although the differences in percentage change between the strains was not statistically significant at this early stage of AAA development. Thoracic and abdominal aortas were analyzed separately to investigate regional effects of SAA deficiency. SAA stimulates vascular SMCs to secrete increased amounts of TGF-β, 19 a multifunctional cytokine believed to play complex roles in AAA and ascending AA development. 40 TGF-β mRNA abundance was significantly lower in both the abdominal and thoracic aortas of SAAKO compared with SAAWT mice after saline and Ang II infusion ( Figure 5A and 5B ). However, aortic TGF-β expression was not altered by 10-day Ang II infusion in either strain. Compared with saline-infused mice, MMP-9 mRNA expression was not significantly altered in abdominal aortas of either SAAWT or SAAKO mice after Ang II infusion ( Figure 5C ), whereas Ang II infusion evoked a significant increase in MMP-13 and MMP-2 expression in both strains ( Figure 5D and 5E). Notably, the induction of MMP-2 mRNA by Ang II was significantly blunted in abdominal aortas of SAAKO mice compared with SAAWT mice ( Figure 5E 
Discussion
Understanding the mechanisms underlying AAA formation and expansion is critical for developing noninterventional treatments that inhibit their progression. Obtaining mechanistic insights through the study of human AAA is impeded by the unavailability of aortic tissue from early stages of the disease and the heterogeneous nature of human AAA tissue. Accordingly, researchers have largely relied on animal models to investigate potential factors mediating AAA initiation and progression. 14, 25 In this study, we used the extensively characterized Ang II infusion model to investigate whether SAA, a circulating inflammatory mediator previously associated in humans with abdominal aortic diameter before aortic dilation, 10 mediates AAA. AAAs induced by Ang II infusion exhibit many features of the human disease, including medial degeneration, inflammation, thrombus formation, and rupture. 25 Our results clearly show that deficiency of SAA reduces Ang II-induced AAA in hypercholesterolemic mice. Both the negative feedback regulation of renin and the hypertensive response elicited by Ang II were normal in SAAKO mice, indicating that reduced AAA in these mice was not because of a general loss in their ability to respond to Ang II. Our findings have implications with regard to the potential use of SAA as a biomarker and therapeutic target for AAA.
We demonstrate that one consequence of Ang II administration in hyperlipidemic mice is an induction of SAA. Within 24 hours after bolus Ang II injection, plasma SAA concentrations increased from almost negligible values at baseline to ≈400 μg/mL. We also noted a statistically significant 15-fold increase in plasma SAA concentration in apoE −/− mice chronically infused with Ang II. Ang II is known to upregulate many inflammatory molecules, including tumor necrosis factor-α and interleukin-6 through an NF-κB dependent pathway. 30 Given abundant evidence that these classical inflammatory molecules potently induce SAA, 41 it is not surprising that Ang II leads to increased SAA expression in mice. SAA levels correlated with plasma interleukin-6 in mice infused with Ang II (r 2 =0.5215; data not shown), consistent with a common pathway for the induction of these 2 acute-phase molecules. Moreover, plasma interleukin-6 concentrations were similar in SAAWT and SAAKO mice after Ang II infusion, in accordance with our previous report that SAAKO mice mount a normal inflammatory response. 42 Notably, the extent of the increase in circulating SAA induced by Ang II is similar to what occurs during a robust endotoxemia-induced acutephase response. 43, 44 The primary source of circulating SAA in mice after acute Ang II injection is likely the liver. Hepatic SAA mRNA abundance was increased ≈26-fold 24 hours after Ang II injection, a time point that may be past the maximal effect of Ang II treatment and thus underestimate the extent of gene induction. In addition to eliciting AAA, Ang II infusion also results in the formation of aneurysms in the ascending aortas of mice. 36 Ascending AAs in Ang II-infused mice share many features in common with those that form in mice harboring a mutant allele of fibrillin-1 and are considered a model of Marfan syndrome. 36, 45 On the other hand, the pathology that develops in the ascending aorta is distinct from Ang II-induced AAA, including the absence of thrombi, elastin fragmentation that is associated with intralaminar expansion rather than transmural degradation, macrophage accumulation throughout the medial layers of the ascending aorta rather than localized recruitment to regions of elastin degradation, and SMC hyperplasia rather than hypertrophy. 36, 46 As noted previously, the marked differences in the pathological characteristics of ascending AA and AAA suggest that distinct pathophysiological pathways may drive their development. 36, 39, 46 In this study, SAA deficiency did not significantly affect the development of Ang II-induced ascending AA, as assessed by measuring the intimal area of the aortic arch region. It should be noted, however, that the incidence of rupture in the thoracic region in our studies was somewhat more pronounced in SAAKO than SAAWT mice (13.9% versus 6.8% incidence, respectively, for thoracic ruptures; 4.7% and 14% incidence, respectively, for abdominal ruptures). Although the incidence of rupture in this animal model is too low for definitive conclusions, it is evident that the effect of SAA deficiency on development of ascending AA versus AAA is distinct. As suggested previously, 36,47 regional differences in the embryonic origin of aortic SMC may give rise to functional diversity, and hence the differential effect of SAA deficiency on Ang II-induced ascending AA and AAA.
In accordance with previous reports, 48 28 -day Ang II infusion produced a significant increase in atherosclerosis in SAAWT mice; SAA deficiency had no significant effect on atherosclerotic lesion area in either saline or Ang II-infused mice. The differential effect of SAA deficiency on Ang IIinduced AAA versus Ang II-induced atherosclerosis is in agreement with previous studies, demonstrating that AAA and atherosclerosis represent rather distinct pathologies that are driven by separate mechanisms. [49] [50] [51] [52] We previously reported that deficiency of SAA does not alter atherosclerotic lipid deposition in apoE −/− mice fed either a normal rodent diet for 50 weeks or an atherosclerotic diet for 12 weeks. 34 Thus, our loss-of-function studies in apoE −/− mice seemingly contradict a large body of epidemiological data associating plasma SAA concentrations with atherosclerotic cardiovascular disease 7, 8, 53 and report that increased SAA expression accelerates atherosclerosis in apoE −/− mice. 16, 54 The lack of reduction of atherosclerosis in SAAKO mice does not negate a role for SAA in atherogenesis but demonstrates that it is not absolutely required. In the setting of severe hypercholesterolemia (such as apoE −/− mice), it seems likely there are redundant pathways to promote inflammation/atherogenesis in the absence of SAA. Furthermore, the low levels of plasma SAA, in addition to the fact that lesions were virtually undetectable in aortas of saline-infused mice, may have precluded our ability to identify a protective effect of SAA deficiency in this study. We cannot rule out the possibility that SAA deficiency exerts an effect on atherosclerosis during more prolonged Ang II infusion. It will be important to determine in future studies whether SAA plays a role in more advanced atherosclerotic lesions, perhaps by modulating plaque stability.
We report positive SAA immunostaining in aneurysmal tissue of humans and Ang II-infused mice. Whether positive SAA immunostaining in aneurysmal tissue reflects localized deposition of circulating SAA or expression by vascular cells, or both, requires further investigation. Although SAA is thought to be primarily expressed by the liver during an acutephase response, nonhepatic cells, including epithelial cells, fibroblasts, endothelial cells, SMCs, and monocytes/macrophages, have all been shown to express SAA in response to inflammatory stimuli. 41, 55, 56 The cellular source(s) of SAA in our studies remain to be established, but our findings suggest that SAA produced at extrahepatic sites, such as vascular SMCs, 56 could play a role in AAA formation through paracrine pathways.
In our studies, SAA was detected in AAA, particularly in regions of elastin breaks and enhanced MMP activity. Our conclusion that SAA mediates Ang II-induced AAA in part by promoting elastin degradation is supported by the finding that the induction of MMP-2 expression and activity by Ang II is significantly blunted in abdominal aortas, but not thoracic aortas, of SAAKO mice. MMP activity is stringently regulated through multiple mechanisms, including the level of production and secretion of latent enzymes, the extent of activation of latent enzymes, and the relative concentration of specific inhibitors that block the activity of secreted MMPs. We determined that MMPs are transcriptionally regulated by purified mouse SAA1.1/2.1, confirming previous reports using a recombinant SAA. [20] [21] [22] Substantial data indicate that augmented MMP activity plays an important role in both human and experimental AAA, 14, 57 although the effectiveness of targeting MMPs for the treatment of human AAA is still under debate. 58 Doxycycline, a broad-spectrum inhibitor of MMPs, reduces the formation of Ang II-induced AAA when given coincident to Ang II infusion. 50, 59 However, according to a more recent report, treatment with doxycycline is not effective in reducing AAA growth or rupture in mice with established AAA. 60 Thus, the role of MMPs in the pathogenesis of Ang II-induced AAA may be particularly important in the early stages of development. The ability of SAA to evoke inflammatory responses, including the induction of chemokines and cytokines implicated in both human and experimental AAA, such as MCP-1 and tumor necrosis factor-α, 61,62 may serve to propagate AAA in later stages of the disease.
The possibility that SAA promotes vascular degradation and AAA formation through mechanisms that are independent of MMPs cannot be ruled out. For example, SAA has been shown to form complexes with cystatin C, 63 an extracellular inhibitor of cysteine proteases, such as cathepsins, that have been implicated in AAA. 64 Whether SAA mediates Ang II-induced pathologies through TGF-β-dependent mechanisms merits consideration. TGF-β is a multifunctional cytokine that affects several cellular processes, including cell growth, differentiation, and migration, as well as remodeling of the extracellular matrix. Interestingly, TGF-β expression was attenuated in both thoracic and abdominal aortic segments of SAAKO mice compared with SAAWT mice, in accordance with an earlier report that SAA stimulates vascular SMCs to secrete TGF-β. 19 Reduced TGF-β in SAAKO mice may affect aortic wall integrity, which could be manifested in complex ways under basal conditions and during chronic Ang II infusion. For example, alterations in arterial stiffness related to reduced TGF-β expression could underlie differences in mean systolic blood pressure observed in SAAKO mice compared with SAAWT mice both before and after Ang II treatment. In this study, increased blood pressure was associated with reduced AAA in SAAKO mice. Although elevated blood pressure is a common feature in the wellestablished AAA model, Ang II-induced AAA can develop independently of a hypertensive response. 65 Morphological and biochemical changes in the artery wall occur during Ang II infusion, 66 including a 60% increase in collagen content, a 74% decrease in elastin content, and breaks in the elastic lamina, all of which result in arterial stiffening; whether TGF-β modulates these responses is unclear. Accumulating experimental evidence points to a complex interaction between Ang II and TGF-β and aortic aneurysm formation. 40 Thus, the diverse effects of TGF-β in thoracic and abdominal aneurysms could underlie the increased thoracic, but not abdominal rupture, in Ang II-infused SAAKO mice. This potential complex interaction between Ang II, TGF-β, and SAA merits further investigation.
In summary, we have established that SAA mediates AAA in a widely used animal model of the disease. A key question that remains to be addressed is whether SAA's main role is in the initiating events of AAA, the subsequent expansion phase, or all stages of AAA formation. Our data that SAA induces macrophages to express factors implicated in AAA suggest that SAA exacerbates AAA progression, given that macrophage infiltration into the abdominal aorta likely occurs after AAA initiation. Future studies will determine whether SAA serves as a useful biomarker for predicting future AAA expansion, and thus, identifies individuals who have high-risk aneurysms and warrant more vigilant monitoring.
